About Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme (GBM) is an aggressive primary brain tumor affecting mostly adults, with a median age at diagnosis of 55 years.

Current ‘standard-of-care’ treatment regimen typically consists of surgery to reduce the tumor mass to the extent safely feasible, followed by radiation therapy and chemotherapy.

About Neuradiab™

Neuradiab™ is an investigational drug currently in the clinical testing process established by the U.S. Food and Drug Administration (FDA) for the evaluation of new drugs. This investigational medication is available through a formal clinical trial to treat glioblastoma multiforme (GBM).

The GLASS-ART Trial is a Phase III clinical trial testing Neuradiab™. The acronym GLASS-ART stands for:

GBM Locoregional Agent Survival Study -
Anti-tenascin Radiolabeled antibody Therapy.

The purpose of the GLASS-ART Trial is to determine if adding the study drug Neuradiab™ to standard treatment regimen, which is composed of surgery followed by radiation and chemotherapy treatment, will be a better treatment than standard therapy alone.